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pathways in the whole blood of patients 
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Abstract 
Background: Osteogenesis imperfecta (OI) is a rare genetic disorder in which the patients suffer from numerous 
fractures, skeletal deformities and bluish sclera. The disorder ranges from a mild form to severe and lethal cases. The 
main objective of this pilot study was to compare the blood transcriptional landscape of OI patients with COL1A1 
pathogenic variants and their healthy relatives, in order to find out different gene expression and dysregulated 
molecular pathways in OI.
Methods: We performed RNA sequencing analysis of whole blood in seven individuals affected with different OI 
severity and their five unaffected relatives from the three families. The data was analyzed using edgeR package of R 
Bioconductor. Functional profiling and pathway analysis of the identified differently expressed genes was performed 
with g:GOSt and MinePath web-based tools.
Results: We identified 114 differently expressed genes. The expression of 79 genes was up-regulated, while 35 genes 
were down-regulated. The functional analysis identified a presence of dysregulated interferon signaling pathways 
(IFI27, IFITM3, RSAD12, GBP7). Additionally, the expressions of the genes related to extracellular matrix organization, Wnt 
signaling, vitamin D metabolism and MAPK-ERK 1/2 pathways were also altered.
Conclusions: The current pilot study successfully captured the differential expression of inflammation and bone 
metabolism pathways in OI patients. This work can contribute to future research of transcriptional bloodomics in OI. 
Transcriptional bloodomics has a strong potential to become a major contributor to the understanding of OI patho-
logical mechanisms, the discovery of phenotype modifying factors, and the identification of new therapeutic targets. 
However, further studies in bigger cohorts of OI patients are needed to confirm the findings of the current work.
Keywords: Osteogenesis imperfecta, Bone fragility, Transcriptome, RNA-seq, Inflammation, Bone metabolism
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Osteogenesis Imperfecta (OI) is a rare bone fragil-
ity disorder. The main features or characteristics of this 
genetic disorder are multiple bone fractures, skeletal 
deformities, bluish sclera and short stature. Addition-
ally, some patients may develop dentinogenesis imper-
fecta (DI), hearing loss, cardiovascular and pulmonary 
Open Access
*Correspondence:  Lidiia.zhytnik@ut.ee
1 Clinic of Traumatology and Orthopedics, Tartu University Hospital, 
Puusepa 8, 51014 Tartu, Estonia
Full list of author information is available at the end of the article
Page 2 of 12Zhytnik et al. BMC Med Genomics          (2020) 13:177 
complications, underlining the complex nature of the dis-
order [1].
OI is classified into five clinical types: type I is the most 
common, being a mild OI with bluish sclera; type II is a 
perinatally lethal OI, type III is a progressively deforming 
OI; type IV is a variable OI with white sclera; and type V 
is an OI with abnormal mineralization. Genetic OI clas-
sification, however, has 20 OI types, which is based on 
the identified molecular mechanisms of the disease. Cor-
relations between OI genotype and phenotype are elu-
sive, and high phenotypic variability between the affected 
individuals with the same variant is present [2–4].
Around 90% of all OI cases are associated with collagen 
type I structural or amount defects because of COL1A1 
and COL1A2 pathogenic variants [5]. Being the main 
structural protein in the human body, collagen type I is 
the main organic component of the bone [6]. An abnor-
mal or reduced amount of collagen type I affects bone 
metabolism in numerous ways. Bone tissue in OI patients 
was described with high bone turnover, hyperminer-
alization, defective extracellular matrix (ECM), hyper-
cellular structure and apoptosis of bone cells [7–9]. In 
recent years, more and more attention is being paid to 
the inflammatory component in OI pathogenesis. Ele-
vated pro-inflammatory cytokine levels were reported in 
a murine model of OI (TGF-β, TNF-α), as well as in OI 
children (platelet counts) [10–12]. Moreover, targeting 
the inflammation is predicted to be a novel therapeutic 
approach for OI [10]. At present, the therapies influenc-
ing TGF-β and Wnt pathways are broadly tested, as no 
cure is available for OI and a search of effective therapies 
for this genetic disorder continues [13, 14].
In their search for new pathological pathways, bio-
markers and therapies, many investigators use whole 
genome RNA sequencing (RNAseq) [15]. The approach 
is sensitive, robust and powerful, and is designed to 
discover differently expressed genes (DEGs) and path-
ways, and is gaining more popularity in research of 
monogenic diseases, mainly for diagnostics [16]. How-
ever, transcriptome analysis is much more promising, 
allowing identification of drug-gene interactions and 
genes modification [17–19].
Although the main affected tissue in OI is bone, obtain-
ing bone biopsies is an invasive procedure and hard to 
access; this is where transcriptional bloodomics comes 
in. Blood transcriptome was proposed as an alternative 
for diseases-specific molecular profiles because it shares 
~ 80% of transcriptome with major tissues and reflects 
the functional state of cells, gene regulation and inflam-
matory response [20–22].
The main aim of the present study was to identify 
DEGs and dysregulated pathways in the whole blood of 
OI patients with COL1A1 pathogenic variants, in order 




A total of 12 individuals from the three OI families, of 
Estonian origin, were enrolled in the study (Fig. 1). Seven 
individuals were affected by OI (OI1-7) and five unaf-
fected individuals from the same families (C1-5) were 
treated as healthy controls. The included families were 
selected from the Osteogenesis Imperfecta database (UT 
OI database) of the Clinic of Traumatology and Orthope-
dics, University of Tartu (Estonia). The characteristics of 
the patients and the controls (lock time 2013) are sum-
marized in Table 1.
Family‑1
Family-1 harbored a heterozygous COL1A1 
c.1821 + 1G > A splice site pathogenic variant. Patient 
Fig. 1 Pedigree trees of three Estonian OI families, which participated in the study. The males are pictured as squares and females as circles. 
Deceased family members are defined with a cross line. Affected individuals are represented with colored-in symbols. Individuals that were 
recruited in the study are depicted in red color
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OI-1 was a 76-year-old female who suffered from OI 
type III. She had a large number of fractures, major 
skeletal deformities, including severe kyphoscoliosis, 
reduced height, triangular face and severe osteoporosis. 
The patient also had blue sclera and hearing loss. Patient 
OI-2 was a 19-year-old grandnephew of OI-1 patient. He 
had OI type I with five fractures, light skeletal deformi-
ties, normal height, bluish sclera and no hearing loss so 
far. C-1 was a healthy half-sister and C-2 was a healthy 
cousin of patient OI-2.
Family‑2
Family-2 had a heterozygous COL1A1 c.750 + 2T> 
A splice site OI-causative variant. Patient OI-3 was a 
46-year-old male with OI type III. He had a total number 
of 50 diagnosed fractures, had bluish sclera and no hear-
ing loss, and had been a wheelchair user since early child-
hood. His four-year-old affected granddaughter, patient 
OI-4, had OI type IV, with a total of four fractures. She 
had no DI or hearing loss. C-3 and C-4 were an unaf-
fected aunt and father of patient OI-4.
Family‑3
Family-3 carried a heterozygous COL1A1 c.1128_delT 
(p.Gly337Alafs*164) frameshift variant. Patient OI-5 was 
a 75-year-old woman with OI type III. She had devel-
oped severe OI with plenty of fractures (n = 30), long 
bones deformities, scoliosis, body disproportions, and 
significantly reduced height. The patient had also devel-
oped mild hearing loss, which might be related to her 
advanced age, although the etiology of the hearing loss 
was unclear. Her 26-year-old granddaughter, patient 
OI-6, had OI type IV, with up to 20 bone fractures and 
normal height. Patient OI-7 was a 2-year-old daughter 
of patient OI-6 who had OI type I and no fractures until 
2013, and was of normal height. The last follow-up con-
firmed the emergence of two fractures between 2013 and 
2020. All the affected individuals in the family had blue 
sclera, and lacked DI. In addition, patients OI-6 and OI-7 
did not suffer from hearing loss. C-5 was a healthy unaf-
fected father of patient OI-7.
RNA extraction and quality assessment
Whole blood was collected in Tempus Blood RNA Tubes 
(Applied Biosystems, Life Technologies Corp., Carls-
bad, CA, USA) from the OI patients and healthy con-
trols. Further processing and total RNA extraction was 
performed with a commercial Tempus Spin RNA Isola-
tion Kit (Ambion, Life Technologies Corp., Carlsbad, 
CA, USA) and RNA purification was performed with 
GLOBINclear™ Kit (Ambion, Life Technologies Corp., 
Carlsbad, CA, USA) following the protocols described 
previously by Maasalu et  al. [23]. The quality of total 
RNA was assessed with Agilent 2100 Bioanalyzer and 
RNA 6000 Nano kit (Agilent Technologies Inc., Santa 
Clara, CA, USA).
RNA‑seq library construction and RNA sequencing
RNA-seq library construction and RNA sequencing anal-
ysis were performed with a SOLiD 5500 W platform (Life 
Technologies Corp., Carlsbad, CA, USA) as described by 
Maasalu et al. [23].
Sequence reads mapping
Raw reads were processed and mapped using Lifescope 
2.5.1 software (Life Technologies Corp., Carlsbad, CA, 
USA). This whole transcriptome analysis workflow gen-
erated output, which includes gene and exon counts, 
alternative splicing, and fusion transcripts. Raw read 
counts per gene were input for further statistical analysis.
Table 1 Characteristics of OI patients and normal controls (lock time 2013)
Sample ID Family no Sex Age Genotype OI type
OI-1 Family-1 Female 76 COL1A1, c.1821 + 1G > A III
OI-2 Family-1 Male 19 COL1A1, c.1821 + 1G > A I
OI-3 Family-2 Male 46 COL1A1, c.750 + 2 T > A III
OI-4 Family-2 Female 4 COL1A1, c.750 + 2 T > A IV
OI-5 Family-3 Female 75 COL1A1, c.1128delT (p.Gly377Alafs*164) III
OI-6 Family-3 Female 26 COL1A1, c.1128delT (p.Gly377Alafs*164) IV
OI-7 Family-3 Female 2 COL1A1, c.1128delT (p.Gly377Alafs*164) I
C-1 Family-1 Female 26 – Healthy
C-2 Family-1 Male 26 – Healthy
C-3 Family-2 Female 12 – Healthy
C-4 Family-2 Male 28 – Healthy
C-5 Family-3 Male 31 – Healthy
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Differential gene expression analysis
Differential expression analysis was conducted using 
R Bioconductor package edgeR (Empirical Analysis of 
Digital gene Expression Data in R, version 3.28.0) stand-
ard workflow with exact test. The edgeR package imple-
ments exact statistical methods and generalized linear 
models for multi-group and multifactorial experiments 
[24]. One feature of the edgeR approach is an empiri-
cal Bayes method that permits the estimation of gene-
specific biological variation, even for experiments with 
minimal levels of biological replication. For the current 
study we applied model-based normalization and used a 
negative binomial model. Testing for differential expres-
sion was done with the exact test. Statistically significant 
genes were indicated with adjusted p value < 0.05 and 
false discovery rate (FDR) < 0.05. To overcome issues of 
biological variability estimation in the presence of mini-
mal number of biological replicates, we used an analysis 
of fold changes. Logarithmic fold change (logFC) > 1.5 or 
< −1.5 was used as an additional cut-off for differential 
gene expression.
Heatmap clustering analysis was generated with the 
mixOmics package in R (Omics Data Integration Project, 
version 6.10.6) [25].
Functional and pathway analysis
Gene pathway analysis was generated with g:Profiler’s 
g:GOSt functional profiler tool (https ://biit.cs.ut.ee/gprof 
iler/gost), a web server for functional enrichment analysis 
and conversions of gene lists [26]. Statistical significance 
was based on a Benjamini–Hochberg FDR approach, 
used to count multiple comparisons in the analysis, with 
a threshold less than 0.05. Annotation data sets for the 
analysis included Reactome, Kyoto Encyclopedia of 
Genes and Genomes (KEGG) and WikiPathways.
Additionally, RNAseq data was analyzed with a web-
based MinePath analysis tool (http://minep ath.org/) for 
the identification of dysregulated functional pathways 
[27, 28]. MinePath analysis is based on the identifica-
tion of differently expressed functional pathways within 
a gene regulatory network using gene expression data 
analysis. The method is based on the identification of the 
phenotype differential sub-paths in molecular pathways.
Results
Differential gene expression
A total number of 114 genes were differently expressed 
(with FDR < 0.05) in the whole blood of OI patients and 
healthy control group (Additional file 1). Out of these, 79 
genes were up-regulated and 35 genes were down-regu-
lated. A total of 39 genes which had logFC > 1.5 or < −1.5 
were considered significant DEGs (Table 2). Out of the 39 
significant DEGs, 31 DEGs were up-regulated and 8 were 
down-regulated.
The five most significant DEGs which were up-regu-
lated in the OI samples were interferon, alpha-inducible 
protein 27 (IFI27, p value 1.73E−29, FDR 4.21E−25), 
MT-RNR2-like 1 (MTRNR2L1, p value 3.49E−28, FDR 
4.25E−24), RAP1 GTP-ase activating protein (RAP1GAP, 
p value 3.26E−21, FDR 2.65E−17), Adhesion G Protein-
Coupled Receptor G7 (ADGRG7, p value 4.01E−19, FDR 
2.44E−15) and Radical S-adenosyl methionine domain 
containing 2 (RSAD2, p value 1.91E−17, FDR 9.31E−14) 
genes.
Statistically significant DEGs were clustered with Heat-
map analysis (Fig.  2). In this figure, the horizontal axis 
represents OI patients (OI1-7) and healthy control (C1-
5) groups, whereas vertical axis represents the expression 
of all 39 identified DEGs. The Heatmap enabled us to see 
clustering of DEGs expression between samples from the 
cohort of OI patients and healthy controls.
Pathway and network analysis
Thirty-six out of the 39 DEGs were analyzed in the path-
way inquiry of g:GOSt tool; three genes (DEFA1B_DUP3, 
DEFA1_DUP3, LOC400931) were not included in the 
analysis because of an unknown gene annotation in avail-
able data sets. A complete list of all statistically signifi-
cant pathways, identified by the g:GOSt tool is shown in 
Additional file  2. Reactome, WikiPathways and KEGG 
analyses identified 39, 13 and 3 altered pathways respec-
tively (Fig. 3).
Reactome annotation revealed an association of 13 
DEGs with the immune system (p-value 1.73E−08), sup-
porting the involvement of a pro-inflammation profile in 
the OI pathological phenotype. Four genes were associ-
ated with the interferon (IFN) signaling pathway (IFI27, 
RSAD2, IFITM3, GBP7; p value 2.17E−04), with particu-
lar involvement of three of them in the IFN-α/β signal-
ing pathway (IFI27, RSAD2, IFITM3; p value 2.70E−04). 
Similarly, cytokine signaling in the immune system 
showed differential expression (IFI27, RSAD2, IFITM3, 
SDC1, GBP7; p value 3.07E−03).
In Reactome analysis, besides the immune system path-
ways, some of the dysregulated networks were connected 
to ECM functioning: ECM organization (MMP8, SDC1, 
CEACAM6; p value 8.14E−03), fibronectin matrix for-
mation (CEACAM6; p value 2.85E−02) and activation of 
matrix metalloproteinase (MMP8; p value 4.851E−02). 
Lastly, some of the identified pathways were linked to 
cell surface interactions with the vascular wall (SDC1, 
CEACAM6; p value 3.50E−03) and heme biosynthesis 
(ALAS2; p value 4.12E−02).
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Heme biosynthesis (ALAS2; p value 3.38E−02) and 
matrix proteinases (MMP8; p value 3.86E−02) path-
ways were also highlighted by WikiPathways analysis. 
Wikipathways analysis also underlined bone metabo-
lism affecting pathways, like regulation of Wnt/β-
catenin signaling by small molecule compounds (DKK3; 
p value 3.86E−02), the LTF danger signal response 
pathway (LTF; 3.86E−02) and non-genomic actions of 
1.25 dihydroxyvitamin D3 (RSAD2, IFI44L; 1.54E−02).
KEGG dataset analysis via g:GOSt tool underlined 
glycine, serine and threonine metabolism (ALAS2, 
GLDC; p value 6.60E−03) and the NOD-like receptor 
signaling pathway (DEFA3, GBP7; p value 4.13E−02).
We also used MinePath analysis for the identifica-
tion of differential pathways and networks. MinePath 
analysis also utilizes the KEGG pathway repository, 
which, additionally, in contrast to g:GOSt, aims to iden-
tify sub-paths that functionally differentiate between 
the expression profiles of samples assigned to differ-
ent phenotypes. The analysis indicated a presence of 
difference among interactions and interconnections of 
DEGs between the OI patients and healthy controls. All 
the identified pathways with p-value < 0.05 (n = 29) are 
available in Additional file 3.
According to MinePath analysis, numerous altered 
networks were related to signaling pathways: MAPK (p 
value 5.92E−11), chemokine (p value 9.67E−09), Osteo-
clast differentiation (p value 5.38E−05), Ras (p value 
1.06E−04), Notch (p value 8.21E−03), TNF (p value 
9.90E−03), vascular smooth muscle contraction (p value 
7.65E−03) and Wnt (p value 3.29E−02) (Additional files 
4 to 8).
Discussion
In the current pilot study, we performed a transcriptome 
analysis of the whole blood in a cohort of OI patients 
with COL1A1 splice site and frameshift pathogenic 
Fig. 2 Heatmap of the 39 significant DEGs, illustrating differences in expressional profiles between OI patients (OI1-7) and healthy controls (C1-5)
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variants and their healthy relatives. We succeeded in 
identifying differential expression of pro-inflammatory 
and bone metabolism pathways in blood cells of individ-
uals affected by OI.
The IFI27 gene—the most significant DEG candidate—
is a member of the IFN type I signaling pathway and 
contributes to apoptosis and signal transduction [6]. The 
gene is associated with numerous chronic inflammatory 
states. Up-regulation of the IFI27 gene was previously 
reported in psoriasis, diffuse large B-cell lymphoma and 
fatigued patients after radiation therapy [29–33].
In addition to the IFI27 gene, IFITM3, RSAD2 and 
GBP7 are the other genes involved in IFN signaling and 
in the other key pathways that are differentially expressed 
in our Reactome analysis. IFN I family includes IFN-α 
and -β, which are the cytokines produced by leukocytes 
and fibroblasts. However, IFN-γ also referred to as IFN 
type II, is known for its involvement in bone metabo-
lism regulation and is produced by T-lymphocytes [34]. 
RSAD2, IFITM3 and IFI27 are involved in IFN-α/β sign-
aling, while the GBP7 gene is involved in IFN-γ signaling.
All three IFNs (IFN-α, -β, -γ) are known to decrease 
collagen synthesis. IFN-α stimulates collagenase 
activation and inhibition of COL1A2 gene expression. 
It is an antagonist of the TGF-β/Smad3 pathway, which 
promotes bone formation and osteoblast differentiation 
[35]. In a row with the other cytokine signaling pathways 
(i.e. Notch, Wnt, fibroblast growth factor), TGF-β/Smad3 
pathway controls osteogenesis and bone tissue homeo-
stasis [36]. IFN-β, for its part, inhibits collagen synthesis 
and activates osteoclastogenesis via IFN-β/STAT1 path-
way activation [37]; while IFN-γ is known to downregu-
late collagen synthesis and to promote bone resorption 
through osteoclastogenesis via activation of a RANKL/
TNFα pathway [38–40].
Our data supports the important role of inflammation 
in OI pathophysiology; this is in addition to the main 
OI genetic variant that might alter the bone phenotype 
of the patients. In addition to IFNs, MAPK, Ras, Notch, 
TNF and Wnt signaling and osteoclast differentiation 
pathways are the other significant pathways found in 
MinePath tool analysis, supporting the alteration of pro-
inflammatory pathways and bone homeostasis in patients 
with COL1A1 OI variants.
According to our results, one of the upregulated DEGs 
was the IFITM3 gene. Interestingly, this gene is closely 
Fig. 3 Pro-inflammation and bone metabolism affecting candidate pathways, which are differently expressed in patients with Osteogenesis 
Imperfecta. Analysis performed with g:GOSt functional profiling tool with Reactome (REACC), WikiPathways (WP) and KEGG annotation sets. 
Illustrated candidate pathways with adjusted p values < 0.05
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related to the IFITM5 gene, which produces a protein of 
the interferon-inducible trans-membrane (IFITM) fam-
ily and is known to cause OI type V (IFITM5, c.-14C > T) 
and VI (IFITM5, c.119C > T, p.(Ser40Trp)) [41–43]. 
However, IFITM3 knockdown did not cause any skeletal 
phenotype; the gene expression was described to affect 
MAPK pathway activation and influence TGF-β-Smads-
MAPK pathway [44, 45]. Similarly, one of the strongest 
candidate DEGs was the RAP1GAP gene, which encodes 
an enzyme that binds to the Rep protein and triggers 
numerous signaling pathways, including the Ras-Raf-
MAPK (ERK1/2) cascade [46, 47]. Recently, a connection 
between OI and alterations in the ERK1/2 pathway was 
described. A homozygous loss of function variant in the 
CCDC134 gene was reported to cause severe OI in three 
Moroccan patients [48]. The gene inhibits ERK1/2 phos-
phorylation, causing down-regulation of COL1A1 and 
OPN in the affected patients. Although the expression of 
the CCDC134 gene was not altered in our patients with 
COL1A1 variants and mild OI, current data provides a 
connection between collagen I expression defect in OI 
and the ERK1/2 pathway. Similarly, the pathway was pre-
viously reported to increase bone loss in various patho-
logical conditions, like arthritis and osteoporosis [23, 49].
The lactoferrin protein, a product of the LTF gene, is 
another DEG with immunomodulatory function and 
associated with the MARK pathway. It participates in 
activation of immune cells at inflammation sites [50], 
and is directly connected to differentiation of osteoblasts, 
anabolic and anti-apoptotic effects on osteoblasts and 
regulation of bone growth [51, 52]. Moreover, lactofer-
rin was reported to inhibit osteoclastogenesis, which is 
considered to be a potential therapeutic target for bone 
diseases, including osteoporosis [53, 54]. Up-regulation 
of the LTF gene could represent a rescue mechanism 
against bone fragility caused by collagen I defects.
One more interesting DEG is the DKK3 gene. Dick-
kopf-related protein 3 is involved in bone formation 
via inhibition of the Wnt signaling pathway [55, 56]. 
Homozygous WNT1 pathogenic variants are a cause of 
OI type XV, whereas heterozygous pathogenic variants 
and variants in the LRP5 gene, associated with the Wnt 
pathway, cause osteoporosis [57, 58]. According to our 
data, the DKK3 gene is downregulated in OI patients, 
which could be speculated as one of the compensatory 
mechanisms, targeted to avoid inhibition of the Wnt 
signaling pathway and increase osteogenesis. Indeed, 
OI bone was described as having a higher turnover and 
increased number of osteoblasts [7].
Our results share a similarity with the study of Zim-
merman et  al. of osteocyte transcriptome in the OI 
murine model [59]. Despite the fact that, in contrast 
to our study, Zimmerman et al. used a bone biopsy to 
explore osteocyte transcriptome, the results of both 
studies agree on dysregulation of the Wnt and TGF-β 
pathways’ in collagen-related OI. However, in contrast 
to the mice study of osteocyte transcriptome, we addi-
tionally identified a role of IFN signaling in the whole 
blood of our human OI patients. We suppose that dif-
ferences might arise due to greater sensitivity of the 
blood tissue towards an inflammatory response.
In our view, the transcriptional pattern observed in 
OI patients not only reflected a pathological state in 
OI patients, like inflammation, but also revealed com-
pensatory mechanisms of the body, helping to resist 
abnormal collagen I synthesis and ultimately an effort 
to modify phenotype. Collagen-related OI mainly 
alters ECM via decreased collagen I deposition or its 
abnormal structure. OI bones are described as having 
a reduced amount of ECM and poor lamellar structure 
[60]. Reactome and WikiPathways analyses highlighted 
that both ECM organization and matrix-metallopro-
teinases pathways were differently expressed in OI 
patients. One of the DEGs in the current network is the 
MMP8 gene that encodes a collagenase, which cleaves 
the triple-helical structure of types I, II and III collagen. 
Upregulation of MMP-8 promotes osteoclast activity 
and differentiation. Interestingly, mice with homozy-
gous mutations in Col1a1 on MMP8 cleavage sites 
showed an increased bone, osteocyte and osteoblast 
deposition [25, 61, 62]. High expression of the MMP8 
gene may point towards a protective mechanism, which 
increases degradation of an abnormal collagen, synthe-
tized by the mutated Col1a1.
We also identified a cross-relation of OI pathophysiol-
ogy and other collagen-related skeletal diseases. Upreg-
ulated expression of the ADGRG7 gene (GPR128) is 
associated with another rare skeletal dysplasia: Fibrogen-
esis Imperfecta Ossium. Similar to OI, this disorder is 
characterized by abnormal collagen, poor bone minerali-
zation, osteopenia/osteoporosis, fractures and bone pain 
[63, 64]. The gene had the highest upregulated logFC, 
which could be a reflection of the common pathological 
state of both the disorders.
Moreover, we identified an altered expression of non-
genomic actions of 1,25-dihydroxyvitamin D3 pathway. 
This finding is particularly interesting because insuffi-
ciency of vitamin D is known to be a common problem 
in OI patients, which may be related to increased bone 
turnover or bisphosphonate treatment [65]. Interest-
ingly, in OI children vitamin D levels were correlated to 
bone density, suggesting that this pathway could be one 
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of the modification factors for OI phenotype [66]. How-
ever, it should be be noted that similar to OI patients, 
individuals with osteoporosis also suffer from vitamin D 
insufficiency, but previous analysis of postmenopausal 
osteoporosis patients did not reveal any dysregulation of 
this pathway [23].
The current study is a pilot study with a limited cohort. 
In order to confirm our findings and to increase its sta-
tistical power, a whole blood transcriptome analysis in 
larger OI cohorts is needed.
The study patients represented relatives from three OI 
families. Thus, our cohort included pediatric and adult 
patients of both sexes. Age and gender are known to 
cause variations in Wnt signaling, as well as MAPK-ERK 
1/2 pathways [67, 68]. Additional analysis of these sub-
groups may reveal new details of bone metabolism varia-
tions between pediatric and adult OI populations, as well 
as male and female OI patients.
Conclusions
In the current pilot study we explored transcriptome pat-
terns of the whole blood serum in OI patients, with the 
aim of revealing the molecular pathways involved in OI 
pathological mechanisms and to explore blood transcrip-
tome potential for profiling a monogenic bone-related 
disorder, like OI.
Most of the significant DEG candidates were associated 
with the IFN signaling pathway (IFI27, IFITM3, RSAD2 
and GBP7). Additionally, we found that dysregulation of 
the other cytokine signaling pathways reflects an inflam-
matory component as a key feature in the blood of OI 
individuals. Furthermore, our data revealed that signifi-
cant changes take place in bone metabolism pathways. 
Upregulation of MMP8, LTF, ADGRG7 and downregula-
tion of DKK3 genes reflected a complex effect of a col-
lagen I OI-related variant on the bone structure and 
homeostasis. Upregulation of the genes connected to 
vitamin D and associated IFN-α stimulation (RSAD2, 
IFI44L) may reflect consequences of an altered vitamin D 
metabolism in OI patients, underlining a complex effect 
of the disorder.
The results of this study are very promising and further 
peripheral blood transcriptome analysis in bigger cohorts 
of OI patients is likely to increase the power of the 
study. Such large-scale studies will help to reveal details 
about inflammation and bone metabolism signatures in 
OI patients and will confirm the findings of the current 
work. Analysis of different OI type subgroups may bring 
extra benefits for potential identification of the biomark-
ers of disease severity and novel therapy targets.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1292 0-020-00825 -7.
Additional file 1. Differently expressed genes with FDR<0.05 in Osteo-
genesis Imperfecta patients compared to healthy controls.
Additional file 2. Functional profiling of the 39 DEGs according to the 
web-based g:GOSt tool. The table includes Reactome, KEGG and WikiPath-
ways annotation sets with pathways’ adjusted p-values <0.05.
Additional file 3. Significantly dysregulated pathways in OI patients com-
pared to healthy controls according to MinePath tool analysis. The table 
includes KEGG annotation with p-values <0.05.
Additional file 4. Significantly dysregulated MAPK signaling pathway 
in OI patients compared to healthy controls according to MinePath tool 
analysis. Green – relations functional in healthy controls, red - relations 
functional in OI patients.
Additional file 5. Significantly dysregulated Osteoclast differentia-
tion pathway in OI patients compared to healthy controls according to 
MinePath tool analysis. Green – relations functional in healthy controls, red 
- relations functional in OI patients.
Additional file 6. Significantly dysregulated vascular smooth muscle con-
traction pathway in OI patients compared to healthy controls according 
to MinePath tool analysis. Green – relations functional in healthy controls, 
red - relations functional in OI patients.
Additional file 7. Significantly dysregulated TNF signaling pathway in 
OI patients compared to healthy controls according to MinePath tool 
analysis. Green – relations functional in healthy controls, red - relations 
functional in OI patients.
Additional file 8. Significantly dysregulated Wnt signaling pathway in 
OI patients compared to healthy controls according to MinePath tool 
analysis. Green – relations functional in healthy controls, red - relations 
functional in OI patients.
Abbreviations
DEGs: Differently expressed genes; DI: Dentinogenesis imperfecta; ECM: 
Extracellular matrix; FDR: False discovery rate; IFN: Interferon; KEGG: Kyoto 
Encyclopedia of Genes and Genomes; logFC: Logarithmic fold change; OI: 
Osteogenesis Imperfecta; RNAseq: RNA sequencing.
Acknowledgements
We would like to thank all patients and their relatives who participated in the 
study. This work is generated within the European Reference Network on rare 
bone diseases (ERN-BOND).
Authors’ contributions
Study design: KM, SK, ER, AM. Study conduct: KM, ER, SK. Data collection: KM, 
AM. Data analysis: LZ, SK, KM. Data interpretation: KM, LZ, SK, ER. Drafting the 
manuscript: LZ, KM, SK. Revising the manuscript content: LZ, KM, SK, ER, AM. 
Approving the final version of the manuscript: LZ, KM, SK, ER, AM. All authors 
have read and approved the manuscript.
Funding
This work was supported by an institutional research grant [IUT20–46] of the 
Estonian Ministry of Education and Research. The funder had no role in the 
study design, data collection and analysis, decision to publish, or preparation 
of the manuscript.
Availability of data and materials
The datasets used and analyzed during the current study are available 
from Gene Expression Omnibus (GEO) repository. Series accession number 
GSE160207 (https ://www.ncbi.nlm.nih.gov/geo/query /acc.cgi?acc=GSE16 
0207).
Page 11 of 12Zhytnik et al. BMC Med Genomics          (2020) 13:177  
Ethics approval and consent to participate
Informed written consent was collected from all subjects and controls, or 
their legal representatives, prior to inclusion in the study and collection of 
their clinical information and biological samples. A written informed consent 
to participate in the study was also obtained from parents or legal guardians 
of participants under the age of 16. The study was conducted in accordance 
with the Helsinki Declaration and authorized by the Ethical Review Committee 
on Human Research of the University of Tartu (Permit No. 221/M-34).
Consent for publication
A written informed consent for publication was obtained from the partici-
pants and parents or legal guardians of any participant under the age of 
18. No identifying images or identifying personal details of participants are 
included in this article.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Clinic of Traumatology and Orthopedics, Tartu University Hospital, Puusepa 8, 
51014 Tartu, Estonia. 2 Department of Traumatology and Orthopedics, Institute 
of Clinical Medicine, University of Tartu, Tartu, Estonia. 3 Estonian Genome 
Centre, University of Tartu, Tartu, Estonia. 4 Perron Institute for Neurological 
and Translational Science, QEII Medical Centre, Nedlands, WA, Australia. 5 Cen-
tre for Molecular Medicine and Innovative Therapeutics, Murdoch University, 
Murdoch, WA, Australia. 
Received: 12 June 2020   Accepted: 15 November 2020
References
 1. Byers PH, Steiner RD. Osteogenesis imperfecta. Annu Rev Med. 
1992;43:269–82. https ://doi.org/10.1146/annur ev.me.43.02019 2.00141 3.
 2. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diag-
nosis, nomenclature and severity assessment. Am J Med Genet A. 
2014;164A:1470–81.
 3. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis 
imperfecta. J Med Genet. 1979;16:101–16. http://www.pubme dcent ral.
nih.gov/artic leren der.fcgi?artid =10127 33&tool=pmcen trez&rende rtype 
=abstr act. Accessed 18 Sep 2014.
 4. Zhytnik L, Maasalu K, Reimand T, Duy BH, Kõks S, Märtson A. Inter- and 
intrafamilial phenotypic variability in individuals with collagen-related 
Osteogenesis Imperfecta. Clin Transl Sci. 2020;:cts.12783. doi:https ://doi.
org/10.1111/cts.12783 .
 5. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, 
et al. Consortium for osteogenesis imperfecta mutations in the helical 
domain of type I collagen: regions rich in lethal mutations align with 
collagen binding sites for integrins and proteoglycans. Hum Mutat. 
2007;28:209–21. https ://doi.org/10.1002/humu.20429 .
 6. Gentili C, Cancedda R. Cartilage and bone extracellular matrix. Curr 
Pharm Des. 2009;15:1334–48. http://www.ncbi.nlm.nih.gov/pubme 
d/19355 972. Accessed 13 Nov 2018.
 7. Rauch F, Travers R, Parfitt a M, Glorieux FH. Static and dynamic bone 
histomorphometry in children with osteogenesis imperfecta. Bone. 
2000;26:581–9.
 8. Roschger P, Fratzl-Zelman N, Misof BM, Glorieux FH, Klaushofer K, Rauch 
F. Evidence that abnormal high bone mineralization in growing children 
with osteogenesis imperfecta is not associated with specific collagen 
mutations. Calcif Tissue Int. 2008;82:263–70. https ://doi.org/10.1007/
s0022 3-008-9113-x.
 9. Fratzl-Zelman N, Barnes AM, Weis M, Carter E, Hefferan TE, Perino G, et al. 
Non-lethal Type VIII osteogenesis imperfecta has elevated bone matrix 
mineralization. J Clin Endocrinol Metab. 2016;101:3516–25. https ://doi.
org/10.1210/jc.2016-1334.
 10. Salter L, Offiah AC, Bishop N. Elevated platelet counts in a cohort of 
children with moderate-severe osteogenesis imperfecta suggest that 
inflammation is present. Arch Dis Child. 2018;103:767–71. https ://doi.
org/10.1136/archd ischi ld-2017-31385 9.
 11. Matthews BG, Roeder E, Wang X, Aguila HL, Lee SK, Grcevic D, et al. Sple-
nomegaly, myeloid lineage expansion and increased osteoclastogenesis 
in osteogenesis imperfecta murine. Bone. 2017;103:1–11.
 12. Grafe I, Yang T, Alexander S, Homan EP, Lietman C, Jiang MM, et al. Exces-
sive transforming growth factor-β 2 signaling is a common mechanism in 
osteogenesis imperfecta. Nat Med. 2014;20:670–5.
 13. Sinder BP, Lloyd WR, Salemi JD, Marini JC, Caird MS, Morris MD, et al. Effect 
of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level 
properties in growing and adult mice while controlling for tissue age. 
Bone. 2016;84:222–9. https ://doi.org/10.1016/j.bone.2016.01.001.
 14. Tauer JT, Abdullah S, Rauch F. Effect of anti-TGF-β treatment in a mouse 
model of severe osteogenesis imperfecta. J Bone Miner Res. 2019;34:207–
14. https ://doi.org/10.1002/jbmr.3617.
 15. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for tran-
scriptomics. Nat Rev Genet. 2009;10:57–63. https ://doi.org/10.1038/nrg24 
84.
 16. Gonorazky HD, Naumenko S, Ramani AK, Nelakuditi V, Mashouri P, Wang 
P, et al. Expanding the boundaries of RNA sequencing as a diagnostic tool 
for rare Mendelian disease. Am J Hum Genet. 2019;104:466–83.
 17. Auslander N, Ramos DM, Zelaya I, Karathia H, Schäffer AA, Crawford TO, 
et al. The GENDULF algorithm: mining transcriptomics to uncover modi-
fier genes for monogenic diseases. SSRN Electron J. 2020.
 18. Mears AJ, Schock SC, Hadwen J, Putos S, Dyment D, Boycott KM, et al. 
Mining the transcriptome for rare disease therapies: a comparison of the 
efficiencies of two data mining approaches and a targeted cell-based 
drug screen. npj Genomic Med. 2017;2:14. doi:https ://doi.org/10.1038/
s4152 5-017-0018-3.
 19. Hadwen J, Schock S, Mears A, Yang R, Charron P, Zhang L, et al. Transcrip-
tomic RNAseq drug screen in cerebrocortical cultures: toward novel 
neurogenetic disease therapies. doi:https ://doi.org/10.1093/hmg/ddy22 
1.
 20. Frésard L, Smail C, Ferraro NM, Teran NA, Li X, Smith KS, et al. Identification 
of rare-disease genes using blood transcriptome sequencing and large 
control cohorts. Nat Med. 2019;25:911–9. https ://doi.org/10.1038/s4159 
1-019-0457-8.
 21. Hecker M. Blood transcriptome profiling captures dysregulated pathways 
and response to treatment in neuroimmunological disease. EBioMedi-
cine. 2019;49:2–3.
 22. Liew C-C, Ma J, Tang H-C, Zheng R, Dempsey AA. The peripheral blood 
transcriptome dynamically reflects system wide biology: a potential diag-
nostic tool. J Lab Clin Med. 2006;147:126–32. https ://doi.org/10.1016/j.
lab.2005.10.005.
 23. Maasalu K, Laius O, Zhytnik L, Kõks S, Prans E, Reimann E, et al. Featured 
article: transcriptional landscape analysis identifies differently expressed 
genes involved in follicle-stimulating hormone induced postmeno-
pausal osteoporosis. Exp Biol Med. 2017;242:203–13. https ://doi.
org/10.1177/15353 70216 67989 9.
 24. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multi-
factor RNA-Seq experiments with respect to biological variation. Nucleic 
Acids Res. 2012;40:4288–97. https ://doi.org/10.1093/nar/gks04 2.
 25. Rohart F, Gautier B, Singh A, Lê Cao K-A. mixOmics: An R package for 
‘omics feature selection and multiple data integration. PLOS Comput Biol. 
2017;13:e1005752. https ://doi.org/10.1371/journ al.pcbi.10057 52.
 26. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. 
g:Profiler: a web server for functional enrichment analysis and conver-
sions of gene lists (2019 update). Nucleic Acids Res. 2019;47:W191–8. 
https ://doi.org/10.1093/nar/gkz36 9.
 27. Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, et al. PANTHER 
version 11: expanded annotation data from Gene Ontology and Reac-
tome pathways, and data analysis tool enhancements. Nucleic Acids Res. 
2017;45:D183–9. https ://doi.org/10.1093/nar/gkw11 38.
 28. Koumakis L, Roussos P, Potamias G. minepath.org: a free interactive path-
way analysis web server. Nucleic Acids Res. 2017;45:W116–21. doi:https ://
doi.org/10.1093/nar/gkx27 8.
 29. Gytz H, Hansen MF, Skovbjerg S, Kristensen ACM, Hørlyck S, Jensen MB, 
et al. Apoptotic properties of the type 1 interferon induced family of 
human mitochondrial membrane ISG12 proteins. Biol Cell. 2017;109:94–
112. https ://doi.org/10.1111/boc.20160 0034.
Page 12 of 12Zhytnik et al. BMC Med Genomics          (2020) 13:177 
 30. Papac-Milicevic N, Breuss JM, Zaujec J, Ryban L, Plyushch T, Wagner GA, 
et al. The interferon stimulated gene 12 inactivates vasculoprotective 
functions of NR4A nuclear receptors. Circ Res. 2012;110:e50-63. https ://
doi.org/10.1161/CIRCR ESAHA .111.25881 4.
 31. Nishiu M, Tomita Y, Nakatsuka SI, Takakuwa T, Iizuka N, Hoshida Y, et al. 
Distinct pattern of gene expression in pyothorax-associated lymphoma 
(PAL), a lymphoma developing in long-standing inflammation. Cancer 
Sci. 2004;95:828–34. https ://doi.org/10.1111/j.1349-7006.2004.tb021 89.x.
 32. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon α-inducible 
protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial 
cancers. J Invest Dermatol. 2004;122:717–21. https ://doi.org/10.1111/
j.0022-202X.2004.22322 .x.
 33. Hsiao CP, Araneta M, Wang XM, Saligan LN. The association of IFI27 
expression and fatigue intensification during localized radiation therapy: 
implication of a para-inflammatory bystander response. Int J Mol Sci. 
2013;14:16943–57.
 34. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated 
signalling. Nat Rev Immunol. 2005;5:375–86.
 35. Inagaki Y, Nemoto T, Kushida M, Sheng Y, Higashi K, Ikeda K, et al. Inter-
feron alfa down-regulates collagen gene transcription and suppresses 
experimental hepatic fibrosis in mice. Hepatology. 2003;38:890–9. https ://
doi.org/10.1053/jhep.2003.50408 .
 36. Wu M, Chen G, Li YP. TGF-β and BMP signaling in osteoblast, skeletal 
development, and bone formation, homeostasis and disease. Bone Res. 
2016;4:16009.
 37. Seeliger C, Schyschka L, Kronbach Z, Wottge A, van Griensven M, Wilde-
mann B, et al. Signaling pathway STAT1 is strongly activated by IFN-β in 
the pathogenesis of osteoporosis. Eur J Med Res. 2015;20:1. https ://doi.
org/10.1186/s4000 1-014-0074-4.
 38. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human 
diploid fibroblast collagen synthesis by interferons. J Clin Invest. 
1984;74:1112–6. https ://doi.org/10.1172/JCI11 1480.
 39. Duncan MR, Berman B. γ interferon is the lymphokine and β interferon 
the monokine responsible for inhibition of fibroblast collagen production 
and late but not early fibroblast proliferation. J Exp Med. 1985;162:516–
27. https ://doi.org/10.1084/jem.162.2.516.
 40. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, et al. IFN-γ stimulates 
osteoclast formation and bone loss in vivo via antigen-driven T cell acti-
vation. J Clin Invest. 2007;117:122–32. https ://doi.org/10.1172/JCI30 074.
 41. Hickford D, Frankenberg S, Shaw G, Renfree MB. Evolution of vertebrate 
interferon inducible transmembrane proteins. BMC Genom. 2012;13:155.
 42. Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, et al. A 
mutation in the 5′-UTR of IFITM5 creates an in-frame start codon and 
causes autosomal-dominant osteogenesis imperfecta type V with hyper-
plastic callus. Am J Hum Genet. 2012;91:349–57. https ://doi.org/10.1016/j.
ajhg.2012.06.011.
 43. Lim JY, Bhatia N, Vasanwala RF, Chay PL, Lim KBL, Khoo PC, et al. A novel 
Ser40Trp variant in IFITM5 in a family with osteogenesis imperfecta 
and review of the literature. Clin Dysmorphol. 2019;:1. doi:https ://doi.
org/10.1097/MCD.00000 00000 00027 9.
 44. Liu X, Chen L, Fan Y, Hong Y, Yang X, Li Y, et al. IFITM3 promotes bone 
metastasis of prostate cancer cells by mediating activation of the TGF-β 
signaling pathway. Cell Death Dis. 2019;10:1–16.
 45. Lange UC, Adams DJ, Lee C, Barton S, Schneider R, Bradley A, et al. 
Normal germ line establishment in mice carrying a deletion of the Ifitm/
Fragilis gene family cluster. Mol Cell Biol. 2008;28:4688–96. https ://doi.
org/10.1128/MCB.00272 -08.
 46. Paratcha G, Ledda F. The GTPase-activating protein Rap1GAP: a new 
player to modulate Ret signaling. Cell Res. 2011;21:217–9.
 47. Li W, Jin B, Cornelius LA, Zhou B, Fu X, Shang D, et al. Inhibitory effects of 
Rap1GAP overexpression on proliferation and migration of endothelial 
cells via ERK and Akt pathways. J Huazhong Univ Sci Technol - Med Sci. 
2011;31:721–7. https ://doi.org/10.1007/s1159 6-011-0667-x.
 48. Dubail J, Brunelle P, Baujat G, Huber C, Doyard M, Michot C, et al. Homozy-
gous loss‐of‐function mutations in CCDC134 are responsible for a severe 
form of osteogenesis imperfecta. J Bone Miner Res. 2020;:jbmr.4011. 
doi:https ://doi.org/10.1002/jbmr.4011.
 49. Lu N, Malemud CJ. Extracellular signal-regulated kinase: a regulator of cell 
growth, inflammation, chondrocyte and bone cell receptor-mediated 
gene expression. International Journal of Molecular Sciences. 2019;20.
 50. Blais A, Malet A, Mikogami T, Tomé D. Bovine Lactoferrin improves bone 
status of ovariectomized mice via immune function modulation. Bone. 
2010;46:S69.
 51. Naot D, Grey A, Reid IR, Cornish J. Lactoferrin–a novel bone growth factor. 
Clin Med Res. 2005;3:93–101.
 52. Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, et al. Lactofer-
rin is a potent regulator of bone cell activity and increases bone forma-
tion in vivo. Endocrinology. 2004;145:4366–74. https ://doi.org/10.1210/
en.2003-1307.
 53. Hou JM, Xue Y, Lin QM. Bovine lactoferrin improves bone mass and 
microstructure in ovariectomized rats via OPG/RANKL/RANK pathway. 
Acta Pharmacol Sin. 2012;33:1277–84.
 54. Li W, Zhu S, Hu J. Bone regeneration is promoted by orally administered 
bovine lactoferrin in a rabbit tibial distraction osteogenesis model. Clin 
Orthop Relat Res. 2015;473:2383–93. https ://doi.org/10.1007/s1199 
9-015-4270-5.
 55. Caricasole A, Ferraro T, Iacovelli L, Barletta E, Caruso A, Melchiorri D, et al. 
Functional characterization of WNT7A signaling in PC12 cells: Interac-
tion with a FZD5-LRP6 receptor complex and modulation by Dickkopf 
proteins. J Biol Chem. 2003;278:37024–31. https ://doi.org/10.1074/jbc.
M3001 91200 .
 56. Aslan H, Ravid-Amir O, Clancy BM, Rezvankhah S, Pittman D, Pelled 
G, et al. Advanced molecular profiling in vivo detects novel function 
of dickkopf-3 in the regulation of bone formation. J Bone Miner Res. 
2006;21:1935–45. https ://doi.org/10.1359/jbmr.06081 9.
 57. Keupp K, Beleggia F, Kayserili H, Barnes AM, Steiner M, Semler O, et al. 
Mutations in WNT1 cause different forms of bone fragility. Am J Hum 
Genet. 2013;92:565–74. https ://doi.org/10.1016/j.ajhg.2013.02.010.
 58. Costantini A, Mäkitie O. Value of rare low bone mass diseases for osteopo-
rosis genetics. Bonekey Rep. 2016;5:773. https ://doi.org/10.1038/bonek 
ey.2015.143.
 59. Zimmerman SM, Dimori M, Heard-Lipsmeyer ME, Morello R. The 
Osteocyte transcriptome is extensively dysregulated in mouse models 
of osteogenesis imperfecta. JBMR Plus. 2019;3:e10171. https ://doi.
org/10.1002/jbm4.10171 .
 60. Baron R, Gertner JM, Lang R, Vignery A. Increased bone turnover 
with decreased bone formation by osteoblasts in children with 
osteogenesis imperfecta tarda. Pediatr Res. 1983;17:204–7. https ://doi.
org/10.1203/00006 450-19830 3000-00007 .
 61. Murphy G, Knäuper V. Relating matrix metalloproteinase structure to 
function: why the “hemopexin” domain? Matrix Biol. 1997;15:511–8. https 
://doi.org/10.1016/s0945 -053x(97)90025 -1.
 62. Zhao W, Byrne MH, Wang Y, Krane SM. Osteocyte and osteoblast apop-
tosis and excessive bone deposition accompany failure of collagenase 
cleavage of collagen. J Clin Invest. 2000;106:941–9.
 63. Bhadada SK, Dhaliwal R, Dhiman V, Rao SD. Fibrogenesis imperfecta 
ossium. Calcif Tissue Int. 2019;104:561–9.
 64. Barron ML, Rybchyn MS, Ramesh S, Mason RS, Fiona Bonar S, Stalley P, 
et al. Clinical, cellular, microscopic, and ultrastructural studies of a case of 
fibrogenesis imperfecta ossium. Bone Res. 2017;5:1–14.
 65. Meena B, Panigrahi I, Marwaha R. PO-0077 Vitamin D deficiency in 
children with osteogenesis imperfecta. Arch Dis Child. 2014;99 Suppl 
2:A275.1-A275.
 66. Edouard T, Glorieux FH, Rauch F. Predictors and correlates of vitamin D 
status in children and adolescents with osteogenesis imperfecta. J Clin 
Endocrinol Metab. 2011;96:3193–8.
 67. Shen L, Zhou S, Glowacki J. Effects of age and gender on WNT gene 
expression in human bone marrow stromal cells. J Cell Biochem. 
2009;106:337–43. https ://doi.org/10.1002/jcb.22010 .
 68. Ehrlichman LK, Ford JW, Roelofs KJ, Tedeschi-Filho W, Futchko JS, Ramac-
ciotti E, et al. Gender-dependent differential phosphorylation in the 
ERK signaling pathway is associated with increased MMP2 activity in 
rat aortic smooth muscle cells. J Surg Res. 2010;160:18–24. https ://doi.
org/10.1016/j.jss.2009.03.095.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
